文献速递消化系统肿瘤

PREMM5模型的开发与验证:用于Lynch综合征的全面风险评估

Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome.
PubMed 文献 · J Clin Oncol · 2017-05-10

研究基于18,734例接受五个Lynch综合征基因检测者的临床和胚系数据,采用多分类逻辑回归开发PREMM5模型,并在1,058例结直肠癌患者中外部验证。模型区分携带者的AUC为0.81(95%CI 0.79-0.82),验证队列AUC为0.83(95%CI 0.75-0.92),决策曲线分析支持对PREMM5评分≥2.5%者进行胚系LS检测。

要点

  • PREMM5可综合评估MLH1、MSH2、MSH6、PMS2和EPCAM五个LS基因的突变风险。
  • 开发队列AUC 0.81(95%CI 0.79-0.82),验证队列AUC 0.83(95%CI 0.75-0.92)。
  • 决策曲线分析支持对PREMM5评分≥2.5%的个体进行LS基因检测。

核心结论

  • PREMM5可提供五个LS基因的全面风险评估,并支持对评分≥2.5%的个体进行LS基因检测。
  • 在此阈值下,PREMM5在识别LS携带者方面优于现有PREMM1,2,6模型,包括那些表型较弱者和未患癌症者。

研究设计与样本

  • PREMM5通过多分类逻辑回归分析18,734例接受全部五个基因检测者的临床和胚系数据开发。
  • 预测因素包括性别、基因检测时年龄以及先证者和家族癌症史。
  • 外部验证在1,058例结直肠癌患者的临床队列中进行。

主要发现

  • 开发队列中1,000例(5%)检出致病突变,包括MLH1(n=306)、MSH2(n=354)、MSH6(n=177)、PMS2(n=141)和EPCAM(n=22)。
  • PREMM5区分携带者与非携带者的AUC为0.81(95%CI 0.79-0.82),验证队列AUC为0.83(95%CI 0.75-0.92)。
  • PMS2突变的预测较其他基因更困难(AUC 0.64;95%CI 0.60-0.68)。
  • PREMM5的性能特征超过PREMM1,2,6。

关键数值与推荐

  • 决策曲线分析支持对PREMM5评分≥2.5%的个体进行胚系LS检测。
  • PREMM5评分≥2.5%为原文推荐的检测阈值。

临床怎么用

  • 对于PREMM5评分≥2.5%的个体,可考虑进行LS基因检测。
  • PREMM5可用于综合评估五个LS基因的突变风险。

局限性

  • PMS2突变的预测较其他基因更困难(AUC 0.64;95%CI 0.60-0.68)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Current Lynch syndrome (LS) prediction models quantify the risk to an individual of carrying a pathogenic germline mutation in three mismatch repair (MMR) genes: MLH1, MSH2, and MSH6. We developed a new prediction model, PREMM5, that incorporates the genes PMS2 and EPCAM to provide comprehensive LS risk assessment. Patients and Methods PREMM5 was developed to predict the likelihood of a mutation in any of the LS genes by using polytomous logistic regression analysis of clinical and germline data from 18,734 individuals who were tested for all five genes. Predictors of mutation status included sex, age at genetic testing, and proband and family cancer histories. Discrimination was evaluated by the area under the receiver operating characteristic curve (AUC), and clinical impact was determined by decision curve analysis; comparisons were made to the existing PREMM1,2,6 model. External validation of PREMM5 was performed in a clinic-based cohort of 1,058 patients with colorectal cancer. Results Pathogenic mutations were detected in 1,000 (5%) of 18,734 patients in the development cohort; mutations included MLH1 (n = 306), MSH2 (n = 354), MSH6 (n = 177), PMS2 (n = 141), and EPCAM (n = 22). PREMM5 distinguished carriers from noncarriers with an AUC of 0.81 (95% CI, 0.79 to 0.82), and performance was similar in the validation cohort (AUC, 0.83; 95% CI, 0.75 to 0.92). Prediction was more difficult for PMS2 mutations (AUC, 0.64; 95% CI, 0.60 to 0.68) than for other genes. Performance characteristics of PREMM5 exceeded those of PREMM1,2,6. Decision curve analysis supported germline LS testing for PREMM5 scores ≥ 2.5%. Conclusion PREMM5 provides comprehensive risk estimation of all five LS genes and supports LS genetic testing for individuals with scores ≥ 2.5%. At this threshold, PREMM5 provides performance that is superior to the existing PREMM1,2,6 model in the identification of carriers of LS, including those with weaker phenotypes and individuals unaffected by cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kastrinos F, Uno H, Ukaegbu C, et al. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017. PMID: 28489507. doi:10.1200/JCO.2016.69.6120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。